300519 新光药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.0937.55812.76413.66012.170
总资产报酬率 ROA (%)2.8166.81711.51412.53611.299
投入资产回报率 ROIC (%)3.0827.53412.72113.61311.910

边际利润分析
销售毛利率 (%)33.99941.27451.85355.70555.301
营业利润率 (%)19.41227.41636.01941.31939.739
息税前利润/营业总收入 (%)16.97720.07032.95635.95136.073
净利润/营业总收入 (%)17.44623.80030.96035.61534.964

收益指标分析
经营活动净收益/利润总额(%)85.68391.07096.51095.32491.167
价值变动净收益/利润总额(%)8.6835.5673.4364.8635.742
营业外收支净额/利润总额(%)1.026-1.330-0.797-0.4742.006

偿债能力分析
流动比率 (X)11.01510.1869.19210.44814.201
速动比率 (X)10.0669.2608.6709.82613.381
资产负债率 (%)8.5869.27410.3229.2437.167
带息债务/全部投入资本 (%)-0.683-0.790-0.878-0.950--
股东权益/带息债务 (%)-14,582.577-12,626.621-11,355.291-10,495.163-9,644.372
股东权益/负债合计 (%)1,064.692978.294868.758981.8411,295.276
利息保障倍数 (X)-6.438-2.873-11.862-6.950-8.052

营运能力分析
应收账款周转天数 (天)12.37722.49620.34519.6100.000
存货周转天数 (天)126.013133.26498.820113.5770.000